Skip to main content
Premium Trial:

Request an Annual Quote

Diaceutics Receives CMS Approval for Increased Data Access

NEW YORK – Diaceutics announced on Wednesday that it has been approved by the US Centers for Medicare & Medicaid Services to receive US medical claims data more frequently.

The data will be integrated into Diaceutics' weekly aggregation of lab data in its DXRX diagnostic commercialization platform to provide customers with "enhanced insight into the testing landscape for precision medicine," the company said in a statement. 

Increasing the frequency of its data feeds will allow the firm's pharmaceutical and diagnostic customers to receive information about testing nearly in real time, allowing them to develop strategies to drive faster access to treatments, UK-based Diaceutics added.

"This step up in data access helps supercharge our service in the market," Diaceutics CEO Peter Keeling said in a statement. "Reducing the lag time for receipt of data will enable us to draw greater insight and value to help identify the best possible testing journey sooner than is currently possible, meaning treatment can be more timely and effective — a key goal for all involved in precision medicine particularly in the wake of COVID-19's profound disruption to testing for cancer and other rare diseases."

Diaceutics' DXRX platform offers data to its customers to help develop and commercialize precision medicine diagnostics. The platform includes lab testing solutions companies such as LGC SeraCare, Targos Molecular Pathology, Histocyte Laboratories, and Alva10, along with external quality assessment organizations.